MP02-18 EFFICACY AND SAFETY OF DA8010, A NOVEL M3 ANTAGONIST, IN PATIENTS WITH OVERACTIVE BLADDER: RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY

Abstract

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Non-neurogenic Voiding Dysfunction I (MP02)1 Sep 2021MP02-18 EFFICACY AND SAFETY OF DA8010, A NOVEL M3 ANTAGONIST, IN PATIENTS WITH OVERACTIVE BLADDER: RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY Hee Seo Son, Joon Chul Kim, Hyeong Gon Kim, Dong Gil Shin, Kyu-Sung Lee, Sangjun Yoo, Ho Young Ryu, Myung-Soo Choo, Ju Tae Seo, Cheol Young Oh, Seong Jin Jeong, Hong Sang Moon, Young-Nam Kwon, and Jang Hwan Kim Hee Seo SonHee Seo Son More articles by this author , Joon Chul KimJoon Chul Kim More articles by this author , Hyeong Gon KimHyeong Gon Kim More articles by this author , Dong Gil ShinDong Gil Shin More articles by this author , Kyu-Sung LeeKyu-Sung Lee More articles by this author , Sangjun YooSangjun Yoo More articles by this author , Ho Young RyuHo Young Ryu More articles by this author , Myung-Soo ChooMyung-Soo Choo More articles by this author , Ju Tae SeoJu Tae Seo More articles by this author , Cheol Young OhCheol Young Oh More articles by this author , Seong Jin JeongSeong Jin Jeong More articles by this author , Hong Sang MoonHong Sang Moon More articles by this author , Young-Nam KwonYoung-Nam Kwon More articles by this author , and Jang Hwan KimJang Hwan Kim More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001963.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: DA8010 is a novel muscarinic M3 receptor antagonist. Prior preclinical studies have verified that DA8010 has high binding affinity for human muscarinic M3 receptor and significant selectivity for bladder smooth muscle cells over salivary gland cells in mice. We aimed to evaluate the clinical efficacy, safety, and optimal dosage of DA8010 in patients with overactive bladder (OAB). METHODS: This study is a phase 2, randomized, double-blind, parallel-group, active reference- and placebo-controlled trial, conducted at 12 centers in South Korea. Male and female patients aged ≥19 years with symptoms of OAB for ≥3 months were enrolled. A total of 306 patients (69.93% female) were randomized to 12 weeks of treatment in 1 of 4 groups: two experimental groups (DA8010 2.5 mg or 5 mg), an active reference group (Solifenacin succinate 5 mg), or a placebo group. Changes in (Δ) 24 hr frequency at 12 weeks (primary end point), episodes of urgency and incontinence, average/maximum voided volume, nocturia, and subjective patient evaluations were analyzed. RESULTS: In the full analysis set, mean (standard deviation) [median] values for Δ 24 hr frequency at 12 weeks were -1.01 (2.44) [-1.33] for placebo, -1.22 (2.05) [-1.33] for DA8010 2.5mg, and -1.67 (2.25) [-1.67] for DA8010 5mg. There was a significant difference between DA8010 5mg and placebo (p=0.0413) (Figure). At 4 and 8 weeks, both DA8010 2.5mg (p=0.0391 at 4 weeks, p=0.0335 at 8 weeks) and DA8010 5mg (p=0.0001 at 4 weeks, p=0.0210 at 8 weeks) showed significant differences in Δ 24 hr frequency, compared with placebo. In Solifenacin 5mg group, Δ 24 hr frequency at 12 weeks was -1.56 (2.17) [-1.67], showing no significant difference from either DA8010 2.5 mg (p=0.4098) or DA8010 5 mg (p=0.8540). DA8010 5mg achieved significant differences in ∆ number of urgency episodes, compared with placebo, at 4 (p=0.0278) and 8 (p=0.0092) weeks. Adverse drug reactions (ADRs) were observed in 3.95% of placebo, 6.67% of DA8010 2.5mg, 18.42% of DA8010 5mg, and 17.33% of Solifenacin 5mg groups. No serious drug related adverse events were observed in any patient. CONCLUSIONS: Both DA8010 2.5mg and 5mg showed clinical efficacy without serious ADRs. A phase 3 study on subdivided efficacy and safety will be conducted. Source of Funding: Dong-A ST Co., Ltd., Seoul, Republic of Korea © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e19-e19 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hee Seo Son More articles by this author Joon Chul Kim More articles by this author Hyeong Gon Kim More articles by this author Dong Gil Shin More articles by this author Kyu-Sung Lee More articles by this author Sangjun Yoo More articles by this author Ho Young Ryu More articles by this author Myung-Soo Choo More articles by this author Ju Tae Seo More articles by this author Cheol Young Oh More articles by this author Seong Jin Jeong More articles by this author Hong Sang Moon More articles by this author Young-Nam Kwon More articles by this author Jang Hwan Kim More articles by this author Expand All Advertisement Loading ...